The Effect of Autologous Autovaccine in Patients With Allergy on House-dust-mite (FIAVS)

Johann Wolfgang Goethe University Hospital

Status and phase: Completed; Phase 1

Conditions: Allergens, House Dust Mites

Treatments: Biological: Injection of autovaccine (Autovaccine Symbiopharm)

Study type: Interventional

Funder types: Other

Identifiers

NCT00677209

AVH-2004/1

Eudra-CT Nr. 2005-005534-12

Details and patient eligibility

About

House dust mite allergy is a common problem, resulting in asthma, chronic swelling of the eyes, and running nose. The investigators test a possibility to immunize subjects sensitized against house dust mite with extracts from their own gut bacteria "auto-vaccination".

Full description

see above

Enrollment: 8 patients

Sex: All

Ages: 18 to 35 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• informed consent
• age 18-35 years
• known allergy on house-dust mite
• GINA 0-1

Exclusion criteria

• anamnestic incompatibility to parts of autovaccine
• asthma > GINA I°
• chronic disease conditions or infections
• pregnancy
• inhalative or systemic steroid use
• any immunosuppressive therapy
• intake of any other probiotic medication (e.g. E.coli nissle 1917)
• participation in any other study at the same time
• substance abuse
• Incapability of understanding the study's purpose and performance
• smoker

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

A

Active Comparator group

Description:

house dust mite allergics will undergo autovaccine immunization

Treatment:

Biological: Injection of autovaccine (Autovaccine Symbiopharm)